These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15095852)

  • 1. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
    Escher JC;
    Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
    Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
    Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
    McKeage K; Goa KL
    Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide for induction of remission in Crohn's disease.
    Otley A; Steinhart AH
    Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
    Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
    Florin TH; Graffner H; Nilsson LG; Persson T
    Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide in the treatment of Crohn's disease: a meta-analysis.
    Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.
    Bar-Meir S; Chowers Y; Lavy A; Abramovitch D; Sternberg A; Leichtmann G; Reshef R; Odes S; Moshkovitz M; Bruck R; Eliakim R; Maoz E; Mittmann U
    Gastroenterology; 1998 Oct; 115(4):835-40. PubMed ID: 9753485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group.
    Ewe K; Böttger T; Buhr HJ; Ecker KW; Otto HF
    Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):277-82. PubMed ID: 10333200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
    Lundin PD; Edsbäcker S; Bergstrand M; Ejderhamn J; Linander H; Högberg L; Persson T; Escher JC; Lindquist B
    Aliment Pharmacol Ther; 2003 Jan; 17(1):85-92. PubMed ID: 12492736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
    Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
    Weigand K; Wagner-Thiessen E; Stolte M
    Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.
    Cohen SA; Aloi M; Arumugam R; Baker R; Bax K; Kierkuś J; Koletzko S; Lionetti P; Persson T; Eklund S
    Curr Med Res Opin; 2017 Jul; 33(7):1261-1268. PubMed ID: 28420280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.